Login
Create Account

Powerpack

Unlock full stockrow access for only $7.9/month and boost yourself as an investor.

Watchlist

Keep track of companies that you follow and research.

10 Years of Data

Full access to our data with predictions and indicators that we calculate daily.

Screener

Full access to our screener with tons of custom values and customizable email notifications.

XLS Exports

Excel export of financials and screeners you define and save.

Viridian Therapeutics, Inc. VRDN

Healthcare — Biotechnology
Insider Buys (last 12m)
Insider Buys alert about insiders buying in the last 12 month

We limit data available in the Overview Report for users who do not have Powerpack

Get access to target analyst prices, predictions, compound annual growth rates and more than four years of historical data.
Register an account and get your Powerpack now or Login

Insider Decisions

Total buys
30.00
Total sells
0.42
in millions of $
Nov 25 Feb 26 May 26 Aug 26
Buy 1 — — — — — — 1 — — — —
Sell — — 1 — — — — — — — 1 —
Insider Ownership
1.41%

Capital & Financial Ratios

Market Cap
2,610.00
Revenue
71.13
Net Income
(386.97)
Free Cash Flow
(335.04)
Net Debt
(739.37)
Current Ratio
16.95
Debt/Equity
0.37
P/E ratio
0.00
P/S ratio
33.37
P/B ratio
4.21
Past 5Y EPS Growth
31.28%
This Y EPS Growth
(18.42%)
Next Y EPS Growth
34.08%
Next 5Y EPS Growth
53.55%
in millions of $

Dividends

Payout Ratio
0.00
Annual Dividend Rate
—
Annual Dividend Yield
—
total individual payouts
2025 ‡‡‡
2024 ‡‡‡
2023 ‡‡‡
2022 ‡‡‡
2021 ‡‡‡
2020 ‡‡‡
2019 ‡‡‡
2017 ‡‡‡
predictions in italic, special payouts not included in total or ratios

Assets vs Liabilities

2023 2024 2025 Q'26
Cash 477.37 717.58 874.65 981.53
Receivables — — — 75.00
Inventory — — — —
Other 0.10 — — —
486.48 738.46 894.23 1,081.27
2023 2024 2025 Q'26
Payables 2.24 2.14 8.68 8.65
ST’ Debt — — — —
Other — — — —
26.64 47.87 70.70 63.79
in millions of $

Compound Annual Growth

10y 5y 3y
Sales ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Cash Flow ‡‡‡ ‡‡‡ ‡‡‡
Earnings ‡‡‡ ‡‡‡ ‡‡‡
Book Value ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡

Revenue

Mar Jun Sep Dec Year
’26 0.14 0.28 — —
—
’25 0.07 0.08 70.57 0.13
70.85
’24 0.07 0.07 0.09 0.07
0.30
’23 0.10 0.07 0.07 0.07
0.31
’22 0.22 0.26 1.20 0.11
1.77
’21 1.45 1.09 0.21 0.21
2.96
’20 0.83 0.17 — 0.05
1.05
in millions of $

Operating Cash Flow

Mar Jun Sep Dec Year
’26 (119.65) (105.32) — —
—
’25 (92.65) (75.37) (84.61) (23.75)
(276.39)
’24 (45.22) (46.06) (67.71) (73.33)
(232.32)
’23 (61.97) (45.21) (38.98) (38.00)
(184.17)
’22 (21.04) (18.09) (20.67) (34.04)
(93.84)
’21 (11.54) (14.63) (11.88) (16.53)
(54.58)
’20 (8.46) (6.79) (5.09) (9.44)
(29.78)
in millions of $

Free Cash Flow

Mar Jun Sep Dec Year
’26 (119.68) (106.63) — —
—
’25 (92.74) (75.41) (84.74) (23.99)
(276.89)
’24 (45.22) (46.16) (68.00) (73.45)
(232.83)
’23 (62.09) (45.54) (39.39) (38.05)
(185.07)
’22 (21.22) (18.38) (20.76) (34.27)
(94.63)
’21 (11.55) (14.61) (12.06) (16.62)
(54.84)
’20 (8.46) (6.79) (5.15) (9.43)
(29.82)
in millions of $

EPS

Mar Jun Sep Dec Year
’26 (0.90) (1.05) — —
—
’25 (0.87) (1.00) (0.34) (1.08)
(3.32)
’24 (0.79) (1.02) (1.15) (0.81)
(3.07)
’23 (1.61) (1.27) (1.09) (1.35)
(5.31)
’22 (0.98) (1.06) (0.86) (1.13)
(4.05)
’21 (2.91) (2.21) (1.25) (1.32)
(6.68)
’20 (2.70) (1.80) (1.50) (23.07)
(31.13)

Target Price Range

High
‡‡‡‡‡
‡‡‡‡
Average
‡‡‡‡‡
‡‡‡‡
Low
‡‡‡
‡‡‡‡

Recommendation Rating

1
1
Buy
2
3
Hold
4
5
Sell
2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028
‡‡‡‡ ‡‡‡‡ ‡‡‡‡ ‡‡‡ ‡‡‡‡ ‡‡‡‡‡ 9.47 10.93 11.40 9.90 — — —
Low Price
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 29.99 39.00 27.20 34.04 — — —
High Price
‡‡‡‡ ‡‡‡‡ ‡‡‡‡ ‡‡‡‡ ‡‡‡‡ ‡‡‡‡ 86 94 143 252 — — —
Employees
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 0.02 0.00 0.00 0.28 — — —
Revenue/Emp
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 1.77 0.31 0.30 70.85 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Revenue
‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ 100.00% 100.00% 100.00% 100.00% — — —
Gross Margin
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (129.87) (237.73) (269.95) (342.60) — — —
EBT
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (7,329.23%) (75,711.46%) (89,387.09%) (483.57%) ‡‡‡ ‡‡‡ ‡‡‡
EBT Margin
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (129.87) (237.73) (269.95) (342.60) ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Net Income
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 0.05 (10.97) (15.11) (6.30) — — —
Depreciation
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 0.06 0.01 0.00 0.84 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Revenue/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (4.05) (5.31) (3.07) (3.32) ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Earnings/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (2.92) (4.12) (3.42) (3.26) — — —
Cash Flow/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (0.02) (0.02) (0.01) (0.01) ‡‡‡ ‡‡‡ ‡‡‡
Capex/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (2.95) (4.14) (3.43) (3.26) — — —
Free CF/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 12.31 9.88 9.89 8.52 — — —
Book Value/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 32.09 44.76 67.89 84.80 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Shares
‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ 0.00 0.00 0.00 0.00 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
PE Ratio
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 516.07 3,185.59 4,309.19 37.25 ‡‡‡ ‡‡‡ ‡‡‡
PS Ratio
‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡ ‡‡‡‡‡ 3.62 4.25 2.70 4.47 ‡‡‡ ‡‡‡ ‡‡‡
PB Ratio
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 279.45 1,732.26 2,003.95 25.73 ‡‡‡‡ ‡‡‡ ‡‡‡‡
EV/Sales
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (5.23) (2.94) (2.60) (6.58) — — —
EV/FCF
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (93.84) (184.17) (232.32) (276.39) ‡‡‡ ‡‡‡ ‡‡‡
Op' Cash Flow
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (0.80) (0.90) (0.51) (0.49) ‡‡‡‡‡ ‡‡‡‡‡ —
Capex
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (94.63) (185.07) (232.83) (276.89) ‡‡‡‡‡ — —
FCF
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 397.82 459.84 690.59 823.54 — — —
Working Cap'
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 5.26 20.21 20.58 49.94 — — —
Total Debt
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (419.29) (457.16) (697.00) (824.71) — — —
Net Debt
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 395.06 442.02 671.64 722.17 — — —
Sh' Equity
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (40.66%) (51.37%) (43.79%) (41.73%) — — —
ROA
‡‡‡ ‡‡‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ 0.00% 0.00% 0.00% 0.00% — — —
ROIC
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (84.66%) (97.35%) (75.17%) (63.87%) — — —
ROE
predictions in italic, sparklines do not include predictions

Analyst Commentary (Summary)

Viridian Therapeutics (VRDN) exemplifies the high-stakes biotech wager, with shares down over 90% from 2017 IPO peaks amid hype that outpaced fading fundamentals. Revenue has collapsed from $8.4 million in 2018 to a mere $302,000 in 2024, plagued by dried-up collaborations and ballooning headcount that slashed productivity metrics like revenue per employee by 98%. Yet analysts forecast a jaw-dropping ramp-up to $328 million by 2027—over 100,000% growth—hinging on Phase 3 success for lead candidate veligrotug in thyroid eye disease, a market overshadowed by Amgen’s Tepezza. This narrative fuels optimism, but deepening losses to -$270 million, relentless cash burn exceeding $200 million annually, and a history of trial setbacks signal profound execution risks.

The balance sheet offers some resilience with $672 million in equity and low debt, yet eroding net cash and projected dilution from ongoing free cash flow deficits raise sustainability concerns, compressing valuations like a 2.7x PB ratio amid sky-high PS multiples. Insider conviction shines through a director’s $10 million buyout, contrasting minor sells, while bullish analyst targets imply 54% upside. As a contrarian play in a sector rife with failures, VRDN tempts as a multibagger on flawless execution—or a value trap on misses; investors should weigh these downside pressures carefully before diving in.

Read full commentary →

Viridian Therapeutics, Inc. (VRDN) Latest News

News by impact score

Fine-tune

7 Aug

3 , 12:05 PM
RBC Capital Markets forecasts minimal revenue growth for Viridian Therapeutics in the second half. Minimal revenue growth forecast signals limited near-term financial upside likely to pressure investor sentiment.

6 Aug

3 , 7:01 AM
Viridian Therapeutics reported second quarter 2026 financial results and highlighted recent business progress. Quarterly financial results and business updates can shift investor views on performance and trajectory.

29 Jul

4 , 10:31 AM
Graves Ophthalmopathy market to grow at 9% CAGR 2026-2036 driven by Viridian Therapeutics LUMVOA approval and emerging therapies. LUMVOA approval directly fuels market expansion and elevates Viridian's competitive standing.

15 Jul

3 , 10:01 AM
Optimism builds around Viridian Therapeutics (VRDN) from Lumvoa’s unique profile. Lumvoa profile drives optimism that may lift near-term sentiment and valuation without altering core operations.

14 Jul

3 , 1:55 PM
Wells Fargo names Viridian Therapeutics (VRDN) among two stocks to buy while staying bullish on the market. Analyst buy recommendation from Wells Fargo can lift near-term investor sentiment and share price for VRDN.

6 Jul

4 , 1:21 PM
Wedbush identifies commercial edge for Viridian (VRDN) after FDA milestone. FDA milestone plus Wedbush endorsement signals major positive shift for Viridian's trajectory.

30 Jun

4 www.biopharmadive.com, 7:33 AM
Analysts argue Viridian Therapeutics holds competitive edge over Amgen in eye drug development showdown. Positive analyst stance on Viridian's edge versus Amgen signals major potential shift in competitive positioning and investor sentiment.

3 , 11:53 AM
RBC analysts project Viridian Therapeutics' Lumvoa will begin generating meaningful revenue in 2027. Forward revenue forecasts for Lumvoa point to moderate influence on future performance and sentiment.

29 Jun

5 , 7:00 AM
Viridian Therapeutics gains FDA approval for and launches Lumvoa (veligrotug-vvze), drawing comments from DRI Healthcare. FDA approval and launch of new drug directly enables commercialization and long-term revenue growth for Viridian.

26 Jun

5 , 6:00 PM
Viridian Therapeutics receives U.S. FDA approval and launches Lumvoa (veligrotug-vvze) for Thyroid Eye Disease treatment. FDA approval and launch of Lumvoa enables commercial revenue and fundamentally strengthens Viridian's market position in thyroid eye disease.

4 stocktwits.com, 6:57 PM
Viridian Therapeutics secures its first FDA approval, triggering a 6% jump in VRDN stock after-hours. First FDA approval enables product launch and drives major revenue growth plus valuation gains.

21 May

4 Insider Monkey, 9:30 AM
Viridian Therapeutics prices upsized concurrent public offerings of common stock and Series B preferred stock for total gross proceeds of $350 million. $350 million capital infusion bolsters cash reserves and funds clinical development for an extended runway.

17 May

4 www.fool.com, 2:52 PM
Viridian Therapeutics has an FDA catalyst set for June 30. One fund reduced its stake in the company by $7 million. June 30 FDA catalyst represents major regulatory event likely to shift Viridian Therapeutics trajectory and investor sentiment.

8 May

5 Simply Wall St., 4:18 AM
Viridian Therapeutics (VRDN) shares surged 25.9% after positive Phase 3 trial results for elegrobart and a new fundraising round. Phase 3 success for elegrobart positions VRDN for potential regulatory approval and commercialization, fundamentally transforming its prospects with added funding runway.

7 May

4 Simply Wall St., 3:41 PM
Viridian Therapeutics, Inc. (NASDAQ:VRDN) reported earnings, prompting analysts to boost their estimates. Analysts boosting estimates after earnings signals significant positive shift in market sentiment and future performance expectations.

6 May

5 www.clinicaltrialsarena.com, 8:13 AM
Viridian Therapeutics (VRDN) stock surged 35% after releasing positive Phase III data for TED treatment. Positive Phase III TED data positions Viridian for regulatory approval and commercialization, fundamentally boosting long-term prospects.

5 www.marketbeat.com, 4:24 AM
Viridian Therapeutics' REVEAL-2 Phase 3 trial met its primary endpoint, delivering proptosis reductions comparable to IV therapy in patients with chronic Thyroid Eye Disease. Phase 3 success in lead subcutaneous TED therapy positions VRDN for regulatory approval and transformative market entry.

4 Business Wire, 11:13 PM
Viridian Therapeutics priced upsized concurrent public offerings of 1.75% Convertible Senior Notes due 2032 and common stock, generating $350.0 million in aggregate gross proceeds. Upsized $350 million capital raise provides substantial funding to advance clinical programs and extend runway, positively impacting financial stability and market perception.

5 May

5 Business Wire, 7:00 AM
Viridian Therapeutics announces positive topline results from the Phase 3 REVEAL-2 clinical trial of elegrobart in chronic thyroid eye disease. Positive Phase 3 topline results for elegrobart in chronic TED position Viridian for regulatory approval and redefine its competitive landscape.

4 Insider Monkey, 9:50 PM
Viridian Therapeutics (VRDN) shares surged 33% on expectations of upcoming drug commercialization. Looming drug commercialization triggered a 33% stock surge, signaling significant strategic advancement and boosted investor sentiment.

4 Investor's Business Daily, 4:24 PM
Viridian Therapeutics (VRDN), up 33% as Amgen rival, details strategy to challenge its dominance in thyroid eye disease treatment market. Viridian's competitive plans against Amgen in thyroid eye disease triggered a 33% stock rise, poised to significantly shift market positioning and investor outlook.

4 Business Wire, 4:05 PM
Viridian Therapeutics announces proposed concurrent public offerings of Convertible Senior Notes due 2032, common stock, and Series B Non-Voting Convertible Preferred Stock. Concurrent offerings of convertible notes, common stock, and preferred stock enable major capital infusion to support pipeline development and operations.

4 investorshub.advfn.com, 10:24 AM
Viridian Therapeutics (VRDN) nears PDUFA decision for its thyroid eye disease (TED) pipeline while advancing developments and reporting Q1 financial results. Nearing PDUFA decision for TED pipeline signals potential regulatory approval, a major milestone likely to significantly alter VRDN's trajectory and investor sentiment.

4 Investor's Business Daily, 9:17 AM
Viridian Therapeutics (VRDN), an Amgen rival, surges 30% as it unveils plans to challenge Amgen's dominance in thyroid eye disease treatment. Strategic plans to disrupt Amgen's thyroid eye disease market leadership boosted VRDN shares 30%.

4 www.biopharmadive.com, 8:04 AM
Viridian Therapeutics' positive data boosts prospects for its thyroid eye disease drug, enhancing potential approval and market position. Positive clinical data significantly improves regulatory and commercial outlook for VRDN's lead candidate in competitive thyroid eye disease space.

4 Investor's Business Daily, 8:00 AM
Viridian Therapeutics, a small biotech firm, positions its eye disease treatment as a potential challenger to Amgen's blockbuster drug, raising questions about its ability to disrupt the market. Viridian's challenge to Amgen's eye disease blockbuster highlights major competitive positioning that could drive significant investor sentiment and stock performance.

4 Business Wire, 7:01 AM
Viridian Therapeutics reported first quarter 2026 financial results and highlighted recent progress. Quarterly financial results and progress highlights signal major updates on operations, pipeline advancement, and investor outlook for VRDN.

21 Apr

4 , 6:04 AM
Analysts have cut revenue estimates for Viridian Therapeutics, Inc. (NASDAQ:VRDN) by 20%. 20% reduction in revenue estimates signals major downward shift in analyst expectations for VRDN's financial outlook and investor confidence.

7 Apr

4 TipRanks, 10:45 AM
Stifel analysts identify a clear path for Viridian Therapeutics (VRDN) to differentiate itself following Amgen's recent data. Stifel's endorsement of VRDN's differentiation from Amgen data signals major competitive and investor sentiment shifts.

4 Zacks, 9:51 AM
Amgen's subcutaneous Tepezza meets primary endpoints in Phase III trial for thyroid eye disease, potentially offering a more convenient alternative to the IV version. Amgen's Phase III win with subcutaneous Tepezza heightens competition in thyroid eye disease, threatening Viridian's veligrotug development and market prospects.
© 2016–2026 stockrow.com Terms and Conditions Indicators Weekly Summary Contact Us